Zomedica Corp (NYSE American:ZOM)
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +253.15% increase from the last price of 0.34.
Similarly, Will ZOM stock be delisted?
(NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or the “Company”) a veterinary diagnostic and pharmaceutical company, today announced that it has received approval of its application to delist its common shares from the TSX Venture Exchange (“TSXV”) effective at the close of business on February 10, 2020.
What is the future of ZOM stock? The Zomedica Pharmaceuticals Corp stock price gained 0.26% on the last trading day (Tuesday, 12th Apr 2022), rising from $0.30 to $0.30.
…
Predicted Opening Price for Zomedica Pharmaceuticals Corp of Wednesday, April 13, 2022.
| Fair opening price April 13, 2022 | Current price |
|---|---|
| $0.30 | $0.30 (Overvalued) |
Thereof, How high does IDEX go?
IDEX stock hit a 2022 high of $1.44 in early January and a low of $0.87 later in the same month. In 2021 its stock price ranged from 88 cents to $5.53. In an interview with Capital.com, Vinod Jain, senior analyst at Aite-Novarica Group, said “the stock could see more volatility due to its current price point”.
Who is Zomedica merging with?
ZOM Stock Booms Upward With PulseVet Acquisition
The company announced the acquisition this morning in a press release, providing some details of the transaction. The acquisition is an all-cash one worth nearly $71 million.
Who invested in Zomedica?
Top 10 Owners of Zomedica Corp
| Stockholder | Stake | Shares bought / sold |
|---|---|---|
| The Vanguard Group, Inc. | 4.14% | +181,358 |
| SSgA Funds Management, Inc. | 2.93% | +5,932,371 |
| BlackRock Fund Advisors | 1.19% | -5,530,082 |
| Cambridge Investment Research Adv… | 1.14% | +845 |
How much cash is Zomedica?
It creates products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica Corp., formerly known as Zomedica Pharmaceuticals Corp., is based in Ann Arbor, Michigan.
…
Compare ZOM With Other Stocks.
| Zomedica Annual Cash on Hand (Millions of US $) | |
|---|---|
| 2020 | $62 |
| 2019 | $1 |
| 2018 | $2 |
| 2017 | $3 |
What is Truforma Zomedica?
Truforma is a blood testing kit for veterinarians. It’s based on bulk acoustic wave (BAW) sensors from Qorvo (NASDAQ:QRVO). The waves are run through pet blood samples to test for adrenal and thyroid diseases.
Is Zomedica a sell?
Considering the 90-day investment horizon and your highly speculative risk level, our recommendation regarding Zomedica Pharmaceuticals Corp is ‘Strong Sell‘.
Is IDEX legitimate?
It is high-speed, authentic, and provides complete security to account holders across the country. IDEX Exchange is the most sought-after trading platform in the digital age in terms of decentralization and community ownership. It offers centralized exchange with safety features of decentralized trading for customers.
Is IDEX a buy or sell?
A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80).
…
Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.93% |
| 2 | Buy | 18.44% |
| 3 | Hold | 9.99% |
| 4 | Sell | 5.61% |
Is IDEX a buy?
Is IDEX a Good Stock to Buy? In my judgment, IDEX is a good stock to buy at current prices. It is relatively cheap compared to other EV car companies such as Nio and Tesla. In addition, it is racking up strategic partnerships along the way, making it a competitive player in a post-fossil-fuel-driven world.
What happen to Zomedica?
Zomedica’s shares have plunged more than 80% after skyrocketing earlier this year. The company has experienced problems with a distribution partner being acquired and a development partner’s delays.
Is Truforma FDA approved?
In April 2020, Zomedica announced that they had completed platform verification of TRUFORMA, which confirms the achievement of instrument design specifications, and follows FDA Medical Device design control guidelines to ensure the product was built correctly.
What is the cost of Truforma?
Based on the revision of the average selling price of immunoassay equipment, the average selling price of TRUFORMA was adjusted up to $8,750, and the average number of units sold annually down to 1,140 units annually.
Who bought Truforma?
Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that it has effected the exchange of all of its outstanding Series 1 Preferred Shares for its common shares and that it continues to progress with its planned commercialization of its TRUFORMA® platform.
How many shares of ZOM are there?
Share Statistics
| Avg Vol (3 month) 3 | 17.3M |
|---|---|
| Shares Outstanding 5 | 979.9M |
| Implied Shares Outstanding 6 | N/A |
| Float 8 | 965.89M |
| % Held by Insiders 1 | 2.63% |
How much does Truforma cost?
Based on the revision of the average selling price of immunoassay equipment, the average selling price of TRUFORMA was adjusted up to $8,750, and the average number of units sold annually down to 1,140 units annually.
How much is ZOM shorted?
Sign Up for a Forever Free Fintel Account
| Short Interest | shares |
|---|---|
| Short Interest Ratio | 7.66 Days to Cover |
| Short Interest % Float | 10.41% |
| Off-Exchange Short Volume | 4,924,528 shares – source: FINRA (inc. Dark Pool volume) |
| Off-Exchange Short Volume Ratio | 48.88% – source: FINRA (inc. Dark Pool volume) |
What do vets say about Truforma?
For its part, Zomedica says that Truforma’s feline-optimized TSH assay “will help veterinarians more readily differentiate between hyperthyroidism and euthyroid sick syndrome.” And, it states that the device’s canine eACTH assay “eliminates the risk of sample transport error and aids in the diagnosis of adrenal disease …
Join TheMoney.co community and don’t forget to share this post !